Mark Krystal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1871239/publications.pdf

Version: 2024-02-01

83 papers	3,363 citations	136950 32 h-index	155660 55 g-index
84 all docs	84 docs citations	84 times ranked	2675 citing authors

#	Article	IF	Citations
1	Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc. Aids, 2022, 36, 11-18.	2.2	8
2	GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0187621.	3.2	13
3	Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0170221.	3.2	11
4	Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral Attachment. Journal of Molecular Biology, 2022, 434, 167395.	4.2	1
5	The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors. Advances in Experimental Medicine and Biology, 2022, 1366, 45-64.	1.6	1
6	Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1. Antimicrobial Agents and Chemotherapy, 2022, 66, e0175121.	3.2	7
7	Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSenseÂ® Entry assay. Journal of Antimicrobial Chemotherapy, 2021, 76, 648-652.	3.0	10
8	Design and exploration of C-3 benzoic acid bioisosteres and alkyl replacements in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum HIV-1 maturation inhibition. Bioorganic and Medicinal Chemistry Letters, 2021, 36, 127823.	2.2	7
9	Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database. Journal of Antimicrobial Chemotherapy, 2021, 76, 2958-2964.	3.0	8
10	Design, synthesis and SAR study of novel C2-pyrazolopyrimidine amides and amide isosteres as allosteric integrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127516.	2.2	6
11	Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors. Bioorganic and Medicinal Chemistry, 2020, 28, 115541.	3.0	6
12	GSK3732394: a Multi-specific Inhibitor of HIV Entry. Journal of Virology, 2019, 93, .	3.4	11
13	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. PLoS ONE, 2019, 14, e0224076.	2.5	15
14	5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 1348-1361.	6.4	32
15	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. , 2019, 14, e0224076.		0
16	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. , 2019, 14, e0224076.		0
17	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. , 2019, 14, e0224076.		0
18	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. , 2019, 14, e0224076.		0

#	Article	IF	Citations
19	The design, synthesis and structure-activity relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1550-1557.	2.2	18
20	Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-Dioxidothiom Acid (GSK3532795, BMS-955176). Journal of Medicinal Chemistry, 2018, 61, 7289-7313.	6.4	23
21	A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin. Journal of Virology, 2018, 92, .	3.4	12
22	Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 299-307.	2.1	34
23	Antiviral Activity, Safety, and Exposureâ€“Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002). Clinical Infectious Diseases, 2017, 65, 442-452.	5.8	18
24	The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitorâ€“Resistant Clinical Isolates. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 52-60.	2.1	10
25	Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
26	C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 1757-1770.	3.0	24
27	Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity. ACS Medicinal Chemistry Letters, 2016, 7, 568-572.	2.8	45
28	Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage. Antimicrobial Agents and Chemotherapy, 2016, 60, 3956-3969.	3.2	58
29	Inhibitors of HIV-1 maturation: Development of structureâ€“activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1925-1930.	2.2	32
30	Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors. PLoS Pathogens, 2016, 12, e1005990.	4.7	19
31	Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age. Pediatric Infectious Disease Journal, 2015, 34, 1355-1360.	2.0	3
32	Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase. ACS Medicinal Chemistry Letters, 2015, 6, 753-757.	2.8	37
33	Homology models of the <scp>HIV</scp>â€1 attachment inhibitor <scp>BMS</scp>â€626529 bound to gp120 suggest a unique mechanism of action. Proteins: Structure, Function and Bioinformatics, 2015, 83, 331-350.	2.6	47
34	Synthesis and evaluation of C2-carbon-linked heterocyclic-5-hydroxy-6-oxo-dihydropyrimidine-4-carboxamides as HIV-1 integrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 717-720.	2.2	32
35	Illuminating HIV gp120-ligand recognition through computationally-driven optimization of antibody-recruiting molecules. Chemical Science, 2014, 5, 2311-2317.	7.4	19
36	Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. Journal of Antimicrobial Chemotherapy, 2014, 69, 573-581.	3.0	56

#	Article	IF	Citations
37	Evaluation of HIV-1 inhibition by stereoisomers and analogues of the sesquiterpenoid hydroquinone peyssonol A. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2192-2196.	2.2	9
38	Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors. Antimicrobial Agents and Chemotherapy, 2013, 57, 4172-4180.	3.2	67
39	In VitroCross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations. Antimicrobial Agents and Chemotherapy, 2013, 57, 5500-5508.	3.2	21
40	Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 7-15.	2.1	38
41	Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects. Journal of Infectious Diseases, 2012, 206, 1002-1011.	4.0	92
42	In VitroAntiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068. Antimicrobial Agents and Chemotherapy, 2012, 56, 3498-3507.	3.2	118
43	Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. Journal of Antimicrobial Chemotherapy, 2012, 67, 465-468.	3.0	18
44	In VivoPatterns of Resistance to the HIV Attachment Inhibitor BMS-488043. Antimicrobial Agents and Chemotherapy, 2011, 55, 729-737.	3.2	47
45	Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects. Antimicrobial Agents and Chemotherapy, 2011, 55, 722-728.	3.2	59
46	Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15366-15371.	7.1	116
47	Solid Phase Synthesis of Novel Pyrrolidinedione Analogs as Potent HIV-1 Integrase Inhibitors. ACS Combinatorial Science, 2010, 12, 84-90.	3.3	23
48	Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-NaÃ¯ve Subjects in the CASTLE Study. PLoS ONE, 2010, 5, e10952.	2.5	108
49	Respiratory syncytial virus fusion inhibitors. Part 7: Structureâ€“activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4857-4862.	2.2	39
50	Entecavir Exhibits Inhibitory Activity against Human Immunodeficiency Virus under Conditions of Reduced Viral Challenge. Antimicrobial Agents and Chemotherapy, 2008, 52, 1759-1767.	3.2	25
51	Changes to the HIV Long Terminal Repeat and to HIV Integrase Differentially Impact HIV Integrase Assembly, Activity, and the Binding of Strand Transfer Inhibitors. Journal of Biological Chemistry, 2007, 282, 31186-31196.	3.4	49
52	Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 895-901.	2.2	63
53	Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4592-4598.	2.2	32
54	Benzyl amide-ketoacid inhibitors of HIV-integrase. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4886-4890.	2.2	14

#	Article	IF	Citations
55	Respiratory syncytial virus fusion inhibitors. Part 6: An examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4784-4790.	2.2	38
56	Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1115-1122.	2.2	38
57	Triketoacid inhibitors of HIV-integrase: A new chemotype useful for probing the integrase pharmacophore. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2920-2924.	2.2	29
58	Exploration of the diketoacid integrase inhibitor chemotype leading to the discovery of the anilide-ketoacids chemotype. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5818-5821.	2.2	8
59	Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. Journal of Antimicrobial Chemotherapy, 2005, 55, 289-292.	3.0	61
60	Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection. Antimicrobial Agents and Chemotherapy, 2004, 48, 2448-2454.	3.2	73
61	Targeting a binding pocket within the trimer-of-hairpins: Small-molecule inhibition of viral fusion. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15046-15051.	7.1	102
62	Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1133-1137.	2.2	35
63	Orally Active Fusion Inhibitor of Respiratory Syncytial Virus. Antimicrobial Agents and Chemotherapy, 2004, 48, 413-422.	3.2	136
64	Development of a photoaffinity label for respiratory syncytial virus inhibitors. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 1105-1116.	1.0	7
65	Fundamental structureâ€“Activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2141-2144.	2.2	61
66	Structureâ€“activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-Trimethyl-5-hydroxy-cyclohexylmethylamine. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3379-3382.	2.2	51
67	An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2393-2396.	2.2	29
68	Salicylamide inhibitors of influenza virus fusion. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1649-1652.	2.2	22
69	Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. Drug Discovery Today, 2000, 5, 241-252.	6.4	33
70	Novel quinolizidine salicylamide influenza fusion inhibitors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2177-2180.	2.2	17
71	pH-Dependent Changes in Photoaffinity Labeling Patterns of the H1 Influenza Virus Hemagglutinin by Using an Inhibitor of Viral Fusion. Journal of Virology, 1999, 73, 1785-1794.	3.4	35
72	Development of antivirals against influenza. Expert Opinion on Investigational Drugs, 1998, 7, 149-165.	4.1	11

#	Article	IF	Citations
73	Differential effect of modified capped RNA substrates on influenza virus transcription. Virus Research, 1997, 50, 65-75.	2.2	7
74	Taking aim at a moving target-inhibitors of influenza virus Part 1 : virus adsorption, entry and uncoating. Drug Discovery Today, 1996, 1, 316-324.	6.4	28
75	Taking aim at a moving target â€" inhibitors of influenza virus Part 2: viral replication, packaging and release. Drug Discovery Today, 1996, 1, 388-397.	6.4	29
76	Use of microphysiometry for analysis of heterologous ion channels expressed in yeast. Nature Biotechnology, 1996, 14, 880-883.	17.5	17
77	Purification and Molecular Structure of RNA Polymerase from Influenza Virus A/PRS1. Journal of Biochemistry, 1990, 107, 624-628.	1.7	104
78	Expression of antisense RNA fails to inhibit influenza virus replication. Virus Research, 1989, 14, 141-159.	2.2	17
79	Complementation and analysis of an NP mutant of influenza virus. Virus Research, 1989, 12, 97-111.	2.2	41
80	Amplification, expression, and packaging of a foreign gene by influenza virus. Cell, 1989, 59, 1107-1113.	28.9	469
81	Expression of the influenza virus matrix protein in bacteria. Virus Research, 1988, 11, 40.	2.2	0
82	A member of a new repeated sequence family which is conserved throughout eucaryotic evolution is found between the human Î´ and Î² globin genes. Nucleic Acids Research, 1981, 9, 5931-5948.	14.5	245
83	Length heterogeneity in a region of the human ribosomal gene spacer is not accompanied by extensive population polymorphism. Journal of Molecular Biology, 1978, 126, 91-104.	4.2	45